CTI BioPharma appoints Alan Burnett lead, myeloid diseases
This article was originally published in Scrip
CTI BioPharma has named Dr Alan K Burnett therapeutic area lead for myeloid disease. Dr Burnett was most recently professor and head of the department of hematology in the Institute of Cancer and Genetics at Cardiff University. He will be responsible for creating and implementing the strategic development program for CTI's compounds in myeloid malignancies with a major focus on supplementing the company's current late-stage development programs in chronic myeloproliferative diseases and international development programs in other myeloid malignancies such as acute myeloid leukemias and myelodysplasia.
You may also be interested in...
It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Derived from Biomedtracker, the Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2020. Data provided by Biomedtracker.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.